November 29, 2016 - By Marie Mckinney
Tenax Therapeutics Inc’s insider Proehl Gerald T on the November 29, 2016 obtained a total of 29,882 shares of the firm that are worth about $49,969 U.S. Dollars. This is based on an average price per share of $1.7 U.S. Dollars. Proehl Gerald T currently holds 29,882 shares or 0.10% of Tenax Therapeutics Inc’s market cap.
The stock increased 5.08% or $0.09 on November 29, hitting $1.86. About 138,658 shares traded hands or 21.00% up from the average. Tenax Therapeutics Inc (NASDAQ:TENX) has declined 36.56% since April 26, 2016 and is downtrending. It has underperformed by 41.82% the S&P500.
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The company has a market cap of $53.20 million. The Firm is focused on identifying, developing and commercializing products for the critical care market. It currently has negative earnings. The Company’s main product is levosimendan.
According to Zacks Investment Research, “Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation and implanted glucose sensing. Tenax Therapeutics Inc., formerly known as Oxygen Biotherapeutics, Inc., is based in United States.”
More recent Tenax Therapeutics Inc (NASDAQ:TENX) news were published by: Businesswire.com which released: “Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan” on October 05, 2016. Also Businesswire.com published the news titled: “Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics (NASDAQ: TENX)” on September 16, 2014. Businesswire.com‘s news article titled: “Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide ..” with publication date: November 03, 2016 was also an interesting one.
Tenax Therapeutics, Inc., incorporated on April 17, 2008, is a specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.